Trade Pharming Group N.V. - PHAR CFD

About Pharming Group N.V.

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pharming Group N.V. revenues decreased 10% to EUR167.7M. Net income decreased 59% to EUR13.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Research and development increase of 76% to EUR59.3M (expense), General and administrative increase of 48% to EUR31.2M (expense).

Equity composition

4/2010, Nominal value changed from EUR 0.5. 07/2012, Nominal value changed from EUR0.04. 3/2013, 1-for-10 reverse stock split (Factor: 0.1 ). 3/2013, Nominal value changed from EUR0.1 to EUR0.01. 11/2016, Rights Issue, 1 new share for every 7 shares held @ 0.205EUR, (Factor: 1.00751).